Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (341-350 of 528) with videos related to

Pageof 53
Sort By:
Molecular Cancer|October 26, 2014
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Cancers|August 26, 2022
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLCJennifer Novak, Ravi Salgia, Howard West, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratioAshwin Shinde, Zachary D Horne, Richard Li, et al.
Nature Clinical Practice. Oncology|January 13, 2006
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutationNicholas W Choong, Sascha Dietrich, Tanguy Y Seiwert, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2002
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destructionF Stephen Hodi, Jan C Schmollinger, Robert J Soiffer, et al.
Oncotarget|October 6, 2017
Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experienceYuan Yuan, Susan E Yost, John Yim, et al.
Oncotarget|January 7, 2017
Genomic mutation-driven metastatic breast cancer therapy: a single center experienceYuan Yuan, Susan E Yost, John Yim, et al.
Translational Lung Cancer Research|June 10, 2024
A novel <i>HLA-DQB2::MET</i> gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case reportDouglas Dias E Silva, Isa Mambetsariev, Jeremy Fricke, et al.
Acta Oncologica (Stockholm, Sweden)|April 9, 2019
Early mortality of stage IV non-small cell lung cancer in the United StatesArya Amini, Vivek Verma, Scott M Glaser, et al.
Plos One|September 16, 2014
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesotheliomaRajani Kanteti, Immanuel Dhanasingh, Ichiro Kawada, et al.
Pageof 53

Showing results (341-350 of 528) with videos related to

Sort By:
Pageof 53
Molecular Cancer|October 26, 2014
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Cancers|August 26, 2022
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLCJennifer Novak, Ravi Salgia, Howard West, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratioAshwin Shinde, Zachary D Horne, Richard Li, et al.
Nature Clinical Practice. Oncology|January 13, 2006
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutationNicholas W Choong, Sascha Dietrich, Tanguy Y Seiwert, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2002
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destructionF Stephen Hodi, Jan C Schmollinger, Robert J Soiffer, et al.
Oncotarget|October 6, 2017
Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experienceYuan Yuan, Susan E Yost, John Yim, et al.
Oncotarget|January 7, 2017
Genomic mutation-driven metastatic breast cancer therapy: a single center experienceYuan Yuan, Susan E Yost, John Yim, et al.
Translational Lung Cancer Research|June 10, 2024
A novel <i>HLA-DQB2::MET</i> gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case reportDouglas Dias E Silva, Isa Mambetsariev, Jeremy Fricke, et al.
Acta Oncologica (Stockholm, Sweden)|April 9, 2019
Early mortality of stage IV non-small cell lung cancer in the United StatesArya Amini, Vivek Verma, Scott M Glaser, et al.
Plos One|September 16, 2014
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesotheliomaRajani Kanteti, Immanuel Dhanasingh, Ichiro Kawada, et al.
Pageof 53